Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Non-Current Assets (2016 - 2025)

China Pharma Holdings' Non-Current Assets history spans 16 years, with the latest figure at $28.7 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 146.64% year-over-year to $28.7 million; the TTM value through Dec 2025 reached $64.6 million, up 51.2%, while the annual FY2025 figure was $28.7 million, 146.64% up from the prior year.
  • Non-Current Assets reached $28.7 million in Q4 2025 per CPHI's latest filing, up from $13.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $28.7 million in Q4 2025 to a low of $9.5 million in Q3 2023.
  • Average Non-Current Assets over 5 years is $12.6 million, with a median of $11.5 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: decreased 24.53% in 2022, then surged 146.64% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $13.6 million in 2021, then fell by 12.81% to $11.8 million in 2022, then dropped by 11.4% to $10.5 million in 2023, then increased by 10.93% to $11.6 million in 2024, then soared by 146.64% to $28.7 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Non-Current Assets are $28.7 million (Q4 2025), $13.5 million (Q3 2025), and $11.1 million (Q2 2025).